Revon Media
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us
No Result
View All Result
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us
No Result
View All Result
Revon Media
No Result
View All Result

Large biopharma companies have US$1.7t dealmaking firepower

Large biopharma companies have US$1.7t dealmaking firepower
Share on FacebookShare on Twitter

Analysts say large drugmakers will have large cash piles to deploy in 2022. So far the biopharma industry has been relatively quiet in terms of mergers and acquisitions.

According to SVB Leerink analyst Geoffrey Porges and his team, 18 large-cap US and European biopharmas will have more than US$500 billion in cash on hand by the end of 2022. The analysts said the funds could be used to strike deals, pay down debt, or provide dividends or share buybacks to shareholders.

The 18 drugmakers’ theoretical firepower, at more than US$1.7 trillion, would be enormous because they can leverage their assets to borrow additional capital, according to the analysts.

When excluding existing debt, 12 of the 18 companies examined by Porges’ team are expected to have more than US$20 billion in cash by the end of 2022. Porges expects Pfizer, Moderna, Johnson & Johnson (J&J), Novartis, and BioNTech to have net cash of more than US$20 billion, even after debt.

Meanwhile, when debt is factored in, the team estimates that Regeneron, Vertex, Novo Nordisk, and GlaxoSmithKline will have between US$11 billion and US$18 billion in cash on hand.

Porges estimates that the 18 biopharma majors will have US$1.72 trillion in M&A capacity based on their cash positions and potential room to take on new debt.

With more than US$200 billion in M&A power, J&J topped the list. Pfizer and Novartis came in second and third with US$175 billion and US$154 billion, respectively. According to the team, AbbVie, GSK, Bristol Myers Squibb, and Merck will each have a market capitalisation of more than US$100 billion.

Using Wall Street consensus estimates, Porges and his team calculated each company’s cash flow by the end of 2022. Major one-time events have benefited some businesses. The sale of Novartis’ 20-year investment in Roche netted the company US$20.7 billion.

The spin-off of GSK and Pfizer’s consumer health joint venture, which is scheduled for mid-2022, is expected to bring in US$27.7 billion and US$16.3 billion, respectively. The analysis did not consider J&J’s planned spinoff of its world-leading consumer health franchise, which the New Jersey corporation expects to take nearly two years to complete.

For example, Pfizer, BioNTech, and Moderna are benefiting greatly from sales of their Covid-19 vaccines and treatments. According to consensus estimates cited by Porges, Pfizer could see total sales of US$84 billion from its BioNTech-partnered Covid-19 vaccine Comirnaty and its yet-to-be-authorised oral antiviral Paxlovid between 2021 and 2023.

However, having cash on hand does not always imply busy M&A activity. Consider 2021: PwC estimated that the biopharmaceutical industry had US$1.47 trillion in M&A firepower at the end of 2020. However, Merck & Co’s US$11.5 billion acquisition of Acceleron was the largest buyout announced in 2021 involving two drugmakers. Jazz Pharmaceuticals’ US$7.2 billion acquisition of GW Pharma was the only other deal worth more than US$5 billion.

Tags: BiopharmaBusinessForeign NewsPharmaceuticalThe Health 2022The Health Jan/FebtheHealth
Previous Post

KPJ Healthcare mobilises resources to aid flood victims in Puchong

Next Post

Harrison.ai raises US$97m, partners Sonic Healthcare

Live Edition Paper

NOV 2020 ePaper

OCT 2020 ePaper


 

Subscribe for free complimentary live editions:

Recent News

  • Controlling the dengue menace
    October 6, 2021
    The complexity of dengue pathogenesis has contributed to the difficulty in […]
  • Dance like no one’s watching
    April 28, 2022
    ‘Dancing molecules’ can successfully repair severe spinal cord injuries after a […]
  • Clearing doubts on the vaccines
    September 30, 2021
    A successful vaccination programme is our exit strategy for this pandemic BY […]
  • Managing Diabetes Through surgery
    January 1, 2021
    Bariatic/metabolic surgery is changing the paradigm of conventional treatment […]
  • Exploring 5G strategies
    February 7, 2022
    The 5G TECH 2021 conference, themed “Digital Economy Recovery through 5G”, was […]

Connect

Office

Revon Media Sdn Bhd
A member of Revongen Corporation
Headquarters
Revongen Corporation Center,
Level 17, Top Glove Tower, No.16,
Persiaran Setia Dagang,Setia Alam,
Seksyen U13, 40170 Shah Alam,
Selangor Darul Ehsan, Malaysia.

Contact

Tel: +603 3359 1166
Fax: +6 03 3358 0303

Copyright © 2021 Revon Media Sdn Bhd. A publication of Revon Media Sdn Bhd. About Us | Contact Us | Privacy Policy | Terms of use

No Result
View All Result
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us

© 2021 Revon Media Sdn Bhd. A publication of Revon Media Sdn Bhd

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist